Henry Gosebruch, Neumora CEO
August 25, 2023 05:06 PM EDTUpdated August 28, 08:28 AM
Financing
Startups

Neu­mora's big neu­ro­science plans head to­ward the Nas­daq in sec­ond PhI­II biotech IPO pitch in 24 hours

Kyle LaHucik

Senior Reporter

The large­ly dor­mant biotech IPO mar­ket start­ed siz­zling Fri­day, with two Phase III drug de­vel­op­ers send­ing in their pitch­es for Nas­daq de­buts this fall …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

No­vo Nordisk to phase out its pro­duc­tion of hu­man in­sulin pens glob­al­ly

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times